Collaborative Cancer Conference

As immunotherapy continues to expand across cancer care, healthcare professionals in both oncology and non-oncology settings increasingly encounter patients experiencing immune-related adverse events (irAEs). This interdisciplinary conference will provide evidence-based education to improve the recognition, evaluation, and management of immunotherapy toxicities while fostering collaboration among oncology specialists, hospitalists, emergency medicine providers, pharmacists, nurses, and other healthcare professionals. Participants will strengthen their ability to identify early warning signs, initiate timely diagnostic evaluation and treatment, and coordinate multidisciplinary care to improve patient safety, preserve treatment continuity, and optimize outcomes for patients receiving cancer immunotherapy.

Who Should Attend:

This conference is intended for physicians, nurse practitioners, physician assistants, pharmacists, pharmacy technicians, registered nurses, advanced practice nurses, medical and pharmacy students, residents, fellows, and other healthcare professionals involved in the care of patients receiving immunotherapy for cancer. The educational content is designed for multidisciplinary clinicians practicing in oncology, emergency medicine, hospital medicine, primary care, urgent care, critical care, and relevant medical and surgical subspecialties.

The conference will be held Oct. 23 in the Cameron Auditorium at Benefis East Campus.

Objectives:

1. Describe the mechanisms of action and toxicity profiles associated with immune checkpoint inhibitors.

2. Recognize common and life-threatening immune-related adverse events (irAEs) affecting major organ systems.

3. Differentiate immune-mediated toxicities from infectious, malignant, and treatment-related mimics.

4. Apply evidence-based guidelines to the grading and initial management of irAEs.

5. Identify appropriate interdisciplinary consultation and escalation strategies from complex toxicities.

6. Implement communication strategies that improve continuity and safety for hospitalized oncology patients receiving immunotherapy.

Continuing Education:

Continuing education (CNE/CME) will be awarded for conference participation. (Estimated 6.5 credits) Pending further application, submission, and review.

Registration:

The cost will be $75 for non Benefis employees, and $35 for employees. All students are free.

Register for the conference here.

Cancellation:

No refunds for cancellations after Oct. 1.